Doctors are looking for better ways to treat advanced colorectal cancer, especially for patients with specific genetic markers like MSI-H or dMMR. These markers often mean the cancer is more likely to respond to a type of treatment called immune checkpoint inhibitors. These drugs help the body's own immune system find and attack cancer cells more effectively.
Recent research looked at how two specific genetic markers, known as RAS and BRAF, affect the success of these treatments. The study looked at over 2,500 patients to see if these markers changed how well the medicine worked. One main finding was that the initial response to the treatment was similar for most patients, regardless of which genetic marker they had.
However, the study found that these markers did change how long the cancer stayed stable over time. For example, patients with the RAS mutation saw a slightly longer period where their cancer did not grow compared to those without that specific mutation. This suggests that the RAS status might play a role in how long the treatment keeps the cancer in check.
In contrast, patients with the BRAF mutation faced more challenges. These patients saw their cancer progress much faster than those without the mutation. Furthermore, the overall survival for patients with the BRAF mutation was notably lower. This information is important because it helps doctors understand that not all patients with the same type of cancer will have the same experience with the same drug.
These findings suggest that doctors can use these genetic markers to better predict how a patient might respond to treatment. By knowing these details early on, medical teams can create more personalized care plans. While more research is needed on some specific combinations of drugs, these results provide a clearer picture of how different genetic profiles impact the journey of patients with advanced colorectal cancer.
